Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Transfusion. 2011 Feb;51(2):306-12. doi: 10.1111/j.1537-2995.2010.02864.x. Epub 2010 Aug 30.
This study was conducted to evaluate the performance of the COM.TEC cell separator (Fresenius HemoCare GmbH) for collecting CD34+ cells in pediatric patients who were intended to have autologous peripheral blood progenitor cell transplantation, with respect to collection variables, prediction power of CD34+ cell yield, and influence on donors.
A total of 26 pediatric solid tumor patients who received mobilization chemotherapy and granulocyte-colony-stimulating factor underwent CD34+ cell collection (n = 96) using the COM.TEC auto mononuclear cell (MNC) program. Patients were divided into a neuroblastoma (NBL) group and a brain tumor group according to the intensity of prior chemotherapy regimens. The collection variables, cellular variables of leukapheresis products, and the peripheral blood cell counts of patients were compared with those acquired using the COBE Spectra (GambroBCT). The CD34+ cell collection efficiency (CE) and the percentage ratios of actual to predicted CD34+ cell yield indicating prediction power were analyzed.
Using the COM.TEC auto MNC program, the processing rate was higher and the product volume was smaller (p < 0.05) than those of the COBE Spectra. Platelet (PLT) reduction in peripheral blood and PLT contamination of the products were significantly lower (p < 0.01). The median CE was less than 60% in both patient groups (50.0 and 48.4%, respectively). The actual collected CD34+ cell yields were medians of 66.9 and 76.1% of the predicted values in NBL group and brain tumor group, respectively.
PBPC collections by the COM.TEC cell separator had advantages of high processing rate, low product volume, and low contamination by PLTs of product. Low PLT loss was observed in pediatric patients who need to collect autologous PBPCs. However, applying CD34+ cell yield prediction was not practical for prospective scheduling of the next collection. More specified data need to be accumulated for more accurate prediction of CD34+ cell yield in pediatric patients.
本研究旨在评估 COM.TEC 细胞分离机（Fresenius HemoCare GmbH）在计划进行自体外周血造血祖细胞移植的儿科患者中采集 CD34+细胞的性能，涉及采集变量、CD34+细胞产量预测能力以及对供者的影响。
共 26 例接受化疗和粒细胞集落刺激因子动员的儿科实体瘤患者采用 COM.TEC 自动单个核细胞（MNC）程序进行 CD34+细胞采集（n=96）。根据化疗方案强度，患者分为神经母细胞瘤（NBL）组和脑肿瘤组。比较 COM.TEC 自动 MNC 程序与 COBE Spectra（GambroBCT）采集的采集变量、白细胞分离产品的细胞学变量以及患者外周血细胞计数。分析 CD34+细胞采集效率（CE）和实际与预测 CD34+细胞产量的百分比比值，以评估预测能力。
使用 COM.TEC 自动 MNC 程序，处理速度更高，产品体积更小（p<0.05）。外周血血小板（PLT）减少和产品中 PLT 污染显著降低（p<0.01）。两组患者的中位 CE 均低于 60%（分别为 50.0%和 48.4%）。NBL 组和脑肿瘤组实际采集的 CD34+细胞产量中位数分别为预测值的 66.9%和 76.1%。
COM.TEC 细胞分离机进行 PBPC 采集具有处理速度高、产品体积小、产品 PLT 污染低的优点。需要采集自体 PBPC 的儿科患者观察到 PLT 丢失较低。然而，应用 CD34+细胞产量预测对于前瞻性安排下一次采集并不实用。需要积累更多特定数据以更准确地预测儿科患者的 CD34+细胞产量。
